OPN1MW and epilepsy: In a clinical trial of treatment-resistant epilepsy, 162 participants included in the safety and tolerability analysis received 25-50 mg/kg/day CBD for 12 weeks and sustained changes in concentrations of concomitant antiepileptic drugs that may have led to status epilepticus [70].